Our portfolio focusing on delivering new drugs for malaria, cryptosporidiosis and Schistosomiasis.
In a project funded by Medicines for Malaria Venture (MMV) we developed DDD498, a highly potent, oral, anti-malarial agent with the potential to be a single dose cure as well as block the transmission of the disease. This compound has completed first-in-human study and (blood-stage) volunteer infection study with MMV and Merck KGaA.
Our cryptosporidiosis project, supported by the MRC is in collaboration with Eisai and has delivered an Optimised Lead molecule suitable for in vivo efficacy.
Our schistosomiasis work is in collaboration with partners in Aberystwyth University and the Helmholtz Institute.